Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of $75.40 million. The enterprise value is -$226.70 million.

Market Cap	75.40M
Enterprise Value	-226.70M

Important Dates

The next estimated earnings date is Monday, May 12, 2025, after market close.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Sutro Biopharma has 83.78 million shares outstanding. The number of shares has increased by 27.70% in one year.

Current Share Class	83.78M
Shares Outstanding	83.78M
Shares Change (YoY)	+27.70%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	1.28%
Owned by Institutions (%)	67.12%
Float	70.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.90
Forward PS	1.66
PB Ratio	1.34
P/TBV Ratio	1.50
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.60, with a Debt / Equity ratio of 0.52.

Current Ratio	2.60
Quick Ratio	2.47
Debt / Equity	0.52
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.37

Financial Efficiency

Return on equity (ROE) is -234.19% and return on invested capital (ROIC) is -118.73%.

Return on Equity (ROE)	-234.19%
Return on Assets (ROA)	-34.74%
Return on Invested Capital (ROIC)	-118.73%
Return on Capital Employed (ROCE)	-93.40%
Revenue Per Employee	$200,139
Profits Per Employee	-$733,745
Employee Count	310
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

In the past 12 months, Sutro Biopharma has paid $2.36 million in taxes.

Income Tax	2.36M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.13% in the last 52 weeks. The beta is 1.70, so Sutro Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.70
52-Week Price Change	-76.13%
50-Day Moving Average	1.08
200-Day Moving Average	2.69
Relative Strength Index (RSI)	57.09
Average Volume (20 Days)	1,729,877

Short Selling Information

The latest short interest is 5.36 million, so 6.40% of the outstanding shares have been sold short.

Short Interest	5.36M
Short Previous Month	4.64M
Short % of Shares Out	6.40%
Short % of Float	7.58%
Short Ratio (days to cover)	2.49

Income Statement

In the last 12 months, Sutro Biopharma had revenue of $62.04 million and -$227.46 million in losses. Loss per share was -$2.96.

Revenue	62.04M
Gross Profit	49.54M
Operating Income	-238.45M
Pretax Income	-97.16M
Net Income	-227.46M
EBITDA	-231.24M
EBIT	-238.45M
Loss Per Share	-$2.96

Full Income Statement

Balance Sheet

The company has $316.90 million in cash and $23.15 million in debt, giving a net cash position of $293.74 million or $3.51 per share.

Cash & Cash Equivalents	316.90M
Total Debt	23.15M
Net Cash	293.74M
Net Cash Per Share	$3.51
Equity (Book Value)	44.60M
Book Value Per Share	0.54
Working Capital	211.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$191.54 million and capital expenditures -$3.10 million, giving a free cash flow of -$194.64 million.

Operating Cash Flow	-191.54M
Capital Expenditures	-3.10M
Free Cash Flow	-194.64M
FCF Per Share	-$2.32

Full Cash Flow Statement

Margins

Gross Margin	79.85%
Operating Margin	-384.34%
Pretax Margin	-362.81%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.70%
Shareholder Yield	-27.70%
Earnings Yield	-339.31%
FCF Yield	-290.34%

Analyst Forecast

The average price target for Sutro Biopharma is $6.83, which is 658.89% higher than the current price. The consensus rating is "Buy".

Price Target	$6.83
Price Target Difference	658.89%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	-2.38%
EPS Growth Forecast (5Y)	-50.08%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sutro Biopharma has an Altman Z-Score of -3.55 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.55
Piotroski F-Score	1